Principles of clinical trial design

Journal of Clinical Oncology

Volumn 20, Issue 18 SUPPL., 2002, Pages

  Nottage, Michelle ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; METASTASIS; PHYSICIAN; PRIORITY JOURNAL; VALIDATION PROCESS;

CLINICAL TRIALS; ETHICS, MEDICAL; HUMANS; PRACTICE GUIDELINES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 0037106391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Prostate cancer screening in the prostate, lung. Colorectal and ovarian cancer screening trial of the National Cancer Institute
2. Nephrectomy followed by interferon alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer
3. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
4. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
5. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the International CATAPULT I Study Group
6. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
7. Analysis of survival by tumor response
8. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes
9. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
10. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer
11. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
12. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
13. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia Bone Marrow Transplant Group
14. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials
15. Selection bias in clinical trials
16. Survival benefits of clinical trials compared to conventional therapy for cancer
17. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
18. Burying of unwanted results: A survey of more than 500 large randomized clinical trials presented at ASCO meetings to determine the probability and causes of failure to publish